ライフサイエンスコーパス: baseline characteristics

1 to account for between-trial differences in baseline characteristics.

2 sed instead of multivariable adjustments for baseline characteristics.

3 s were used to compensate for differences in baseline characteristics.

4 sulted in 355 pairs of patients with similar baseline characteristics.

5 The groups had similar baseline characteristics.

6 for significant between-group differences in baseline characteristics.

7 (n = 696) patients with DLBCL had comparable baseline characteristics.

8 g was used to assemble a cohort with similar baseline characteristics.

9 sed to select subpopulations with comparable baseline characteristics.

10 o assemble a cohort of patients with similar baseline characteristics.

11 was applied to select 2 groups with similar baseline characteristics.

12 re used to compensate for the differences in baseline characteristics.

13 Both groups were similar regarding baseline characteristics.

14 g were used to compensate for differences in baseline characteristics.

15 was performed to account for differences in baseline characteristics.

16 neither target, adjusting for differences in baseline characteristics.

17 s (PR) were adjusted for cluster effects and baseline characteristics.

18 e used to compensate for differences in some baseline characteristics.

19 The groups were well matched for baseline characteristics.

20 t significantly altered after adjustment for baseline characteristics.

21 ality incrementally and independently of all baseline characteristics.

22 eronegative participants while adjusting for baseline characteristics.

23 score matching to control for differences in baseline characteristics.

24 log-linear mixed effects models adjusted for baseline characteristics.

25 sible due to differences in study design and baseline characteristics.

26 ensity score matching was used to adjust for baseline characteristics.

27 e <70 versus >/=70 beats/min, balanced on 58 baseline characteristics.

28 ving and not receiving CCBs, balanced on 114 baseline characteristics.

29 They were matched for 6 baseline characteristics.

30 n matched 1:1 based on propensity scoring of baseline characteristics.

31 nsity within 28 days in an adjusted model of baseline characteristics.

32 The 2 groups were well-matched in terms of baseline characteristics.

33 The 2 groups were well balanced in terms of baseline characteristics.

34 ching was used to correct for differences in baseline characteristics.

35 black and white patients after adjusting for baseline characteristics.

36 t patients significantly after adjusting for baseline characteristics.

37 except sudden death in a model including all baseline characteristics.

38 The 2 groups had similar baseline characteristics (1.5 compared with 1.0 kcal/mL)

39 Baseline characteristics, 30-day to 1-year all-cause mor

40 atment groups may not be comparable in their baseline characteristics, a phenomenon known as confound

41 population with no significant difference in baseline characteristics (age, 79+/-8.2 years; 60% women

42 Information regarding baseline characteristics, all-cause mortality, and readm

43 chical Cox modeling to adjust for imbalanced baseline characteristics, allocation to dexmedetomidine

44 t weighting was used to balance more than 60 baseline characteristics among patients in the 4 drug co

45 Baseline characteristics among patients with nonshockabl

46 There were no significant differences in baseline characteristics among the 4 groups, thus confir

47 cant differences in patient demographics and baseline characteristics among the 4 treatment groups.

48 ciation between CTG expansion size and other baseline characteristics and (1) cardiac involvement at

49 models that accounted for variations in (1) baseline characteristics and (2) both baseline and surgi

50 Baseline characteristics and 2-year outcomes of TAVR ver

51 Baseline characteristics and clinical as well as paracli

52 ncluded to evaluate selection criteria used, baseline characteristics and clinical outcomes at 3-mont

53 gens with ivacaftor and correlates them with baseline characteristics and clinical response.

54 subgroups that differed significantly in all baseline characteristics and clinical trajectories, desp

55 ortality hazard ratios after controlling for baseline characteristics and disease severity.

56 ional hazards regression models adjusted for baseline characteristics and drugs to investigate the as

57 Associations of baseline characteristics and early VA response (week 4 o

58 Baseline characteristics and factors on treatment were a

59 Data were reviewed for baseline characteristics and incident mortality, heart t

60 p and 118 in the control group, with similar baseline characteristics and injury profiles.

61 different trajectories of patients based on baseline characteristics and intermediary events.

62 We describe baseline characteristics and long-term follow-up in pati

63 Baseline characteristics and mean tacrolimus trough leve

64 Baseline characteristics and medication use were compare

65 After adjustment for baseline characteristics and multiple fractures, the rel

66 nd identification of the association between baseline characteristics and occurence structural progre

67 Relationships of baseline characteristics and operative conduct with morb

68 Baseline characteristics and outcome were compared accor

69 bstracts for observational studies comparing baseline characteristics and outcomes in patients with N

70 linked to Medicare was used to determine the baseline characteristics and outcomes of 9093 patients w

71 Baseline characteristics and outcomes were compared.

72 Baseline characteristics and overall survival were compa

73 allic DES and could be determined by patient baseline characteristics and periprocedural factors.

74 Baseline characteristics and physiologic components of t

75 D compared with those without, adjusting for baseline characteristics and postprocedure medications.

76 ective and in-hospital time horizon; derived baseline characteristics and probabilities of intensive

77 Baseline characteristics and procedure-related complicat

78 We studied the association between baseline characteristics and rates of cardiovascular dea

79 Baseline characteristics and reflux parameters of MII st

80 ed by joinpoint regression were compared for baseline characteristics and resource use, including tot

81 njections administered during the OLE versus baseline characteristics and response to treatment durin

82 Baseline characteristics and risk categories were well b

83 to control for between-group differences in baseline characteristics and risk.

84 ssion was used to study associations between baseline characteristics and the occurrence of structura

85 Despite differences in baseline characteristics and the response rate between t

86 an initial risk group on the basis of their baseline characteristics and then underwent 32 days of i

87 Baseline characteristics and therapeutic interventions f

88 Summary statistics of RIDE/RISE baseline characteristics and treatment responses were ge

89 Baseline characteristics and treatments of RELAX-AHF-typ

90 usted for calendar time, admitting hospital, baseline characteristics, and in-hospital revascularizat

91 To investigate baseline characteristics associated with 6-month VA and

92 Baseline characteristics associated with an increased ri

93 Baseline characteristics associated with an increased ri

94 Baseline characteristics associated with persistent on-t

95 We compared baseline characteristics at listing and at HT and used C

96 After adjustment for baseline characteristics, AVR+ARE was not associated wit

97 = 359; MAP plus IFN-alpha-2b, n = 357), with baseline characteristics balanced by arm.

98 There were no significant differences in baseline characteristics between both groups.

99 There were no significant differences in the baseline characteristics between both the groups.

100 (n = 251) conditions, with no differences in baseline characteristics between conditions.

101 Baseline characteristics between groups were similar.

102 Baseline characteristics between groups were well balanc

103 There were no differences in baseline characteristics between groups.

104 count for observed systematic differences in baseline characteristics between patients treated and th

105 alysis was used to adjust for differences in baseline characteristics between patients with and witho

106 There were no differences in baseline characteristics between the 2 groups.

107 There were no differences in baseline characteristics between the 3 groups.

108 ial regression, adjusting for the imbalanced baseline characteristics between the groups.

109 There were some differences in the baseline characteristics between the groups: higher prop

110 Differences in baseline characteristics between those who did and did n

111 Baseline characteristics between treatment groups were s

112 However, after adjustment for baseline characteristics, black (adjusted odds ratio = 0

113 ska Native patients; but after adjusting for baseline characteristics, black race and Hispanic ethnic

114 Baseline characteristics, blood samples, and angiography

115 with standardized protocols and adjusted for baseline characteristics by Cox regression.

116 Baseline characteristics can be used to predict subseque

117 8 was higher in subgroups with the following baseline characteristics compared with the complementary

118 After adjustment for multiple baseline characteristics, compared with no-VHD patients

119 All four clinical baseline characteristics constituting the MIPI, age, per

120 Data on baseline characteristics (country, study population, eli

121 Baseline characteristics, days on study PN and daily mac

122 Propensity score analysis with matched baseline characteristics demonstrated superior median (5

123 The baseline characteristics, development of early dermatolo

124 Baseline characteristics did not differ between the rand

125 Baseline characteristics did not differ by trial arm exc

126 Baseline characteristics did not differ in these 2 group

127 The baseline characteristics did not differ significantly be

128 Baseline characteristics differed between the sexes.

129 trations of 500 pg/mL or higher, we compared baseline characteristics, duration of heparin treatment,

130 Baseline characteristics, duration of heparin treatment,

131 fficacy International Trial and adjusted for baseline characteristics during 6 years' median follow-u

132 elected from a bank of messages according to baseline characteristics (eg, smoking) and delivered via

133 Baseline characteristics following stratification, inclu

134 ase data for rates of STEMI, treatments, and baseline characteristics from patients attending each sa

135 Select baseline characteristics have predictive value for visua

136 Baseline characteristics, hemodynamic and clinical chang

137 djusted life years according to all assessed baseline characteristics (ICU admission after elective s

138 Multivariable analysis of baseline characteristics identified high marrow tumor bu

139 gy Diary users were able to properly provide baseline characteristics (ii) simple phenotypic characte

140 Baseline characteristics, implant strategies, hemodynami

141 bleeding in the 1-year mortality model with baseline characteristics improved it to an extent compar

142 patients with cardiogenic shock with similar baseline characteristics in New York and Michigan.

143 Baseline characteristics, in-hospital complications, and

144 Median baseline characteristics included age 36 years (IQR 30-4

145 Baseline characteristics included age of 83 years, 42% f

146 no significant differences between groups in baseline characteristics including age, sex, site of inf

147 Baseline characteristics including LOAELs were comparabl

148 Propensity matching for 16 baseline characteristics, including diagnosis, yielded 1

149 Treatment arms were well matched for baseline characteristics, including FACT-B total score (

150 Baseline characteristics, including gender, age, HCV-RNA

151 Subjects' baseline characteristics, including IR indexes, were sim

152 for EDS was generated, which included seven baseline characteristics, including non-motor symptoms a

153 d preadmission diuretic therapy, traditional baseline characteristics, including right heart catheter

154 In the matched cohort, baseline characteristics, including Society of Thoracic

155 Baseline characteristics indicated more severe disease i

156 After adjustment for other baseline characteristics, low FVIII remained associated

157 th those undergoing optical keratoplasty for baseline characteristics, management details, and visual

158 ce-eligible patients who were balanced on 28 baseline characteristics (mean age, 79 years; 58% women;

159 We adjusted the baseline characteristics, medical treatment, and drug ad

160 ltivariate regression models including urban baseline characteristics, meteorological variables, and

161 We then assessed whether baseline characteristics moderated the intervention's ef

162 Baseline characteristics, MSNA and haemodynamics were si

163 However, when accounting for differences in baseline characteristics, multiple fractures, and/or eve

164 attern remained similar after adjustment for baseline characteristics (odds ratio in the SIRS-positiv

165 There were no between-group differences in baseline characteristics of 1,489 eligible patients with

166 Baseline characteristics of 984 patients with LF AS incl

167 w-up through December 31, 2015, compared the baseline characteristics of AYA (13-39 years old) and OA

168 Detailed baseline characteristics of both cohorts are presented,

169 Baseline characteristics of CLD patients who underwent T

170 The baseline characteristics of gender, age, and glaucoma di

171 s on protein structure and function, and the baseline characteristics of indels in 2504 individuals o

172 To describe the design and baseline characteristics of participants in the Study of

173 This study aimed to determine the baseline characteristics of participants with heart fail

174 There were no differences in the baseline characteristics of patients enrolled in the ext

175 The aim of this study was to compare baseline characteristics of patients receiving intravitr

176 The baseline characteristics of patients seen by each provid

177 Baseline characteristics of patients were comparable; al

178 ysis and network-based statistics to explore baseline characteristics of patients who subsequently re

179 patients with HCV genotype 1 infection with baseline characteristics of poor response.

180 Baseline characteristics of previously treated DEX 0.7 (

181 The baseline characteristics of the 2 treatment arms were si

182 f the Offspring Study and presented selected baseline characteristics of the cohort.

183 Baseline characteristics of the groups were similar.

184 After adjustment for changes in the baseline characteristics of the infants over time, both

185 The baseline characteristics of the patients, need and type

186 up of 49 asymptomatic DMEK eyes that matched baseline characteristics of the rejection group.

187 Similarities of the baseline characteristics of the SCORE2 population to oth

188 Baseline characteristics of the two groups were similar.

189 The baseline characteristics of the two groups were similar.

190 Baseline characteristics, OMG symptoms, results of AChR

191 Baseline characteristics on risk factor levels were obta

192 We identified no effect of baseline characteristics on the associations between com

193 roportion of patients, and did not relate to baseline characteristics or disease progression, but add

194 There were no differences in baseline characteristics or follow-up among the groups.

195 There were no differences in baseline characteristics or follow-up duration between t

196 f 2-year vision outcomes than either several baseline characteristics or week 4 response.

197 After adjustment for baseline characteristics, patients enrolled based on pre

198 After adjustment for baseline characteristics, patients enrolled based on pre

199 After adjustments for baseline characteristics, patients in the systematic str

200 After adjustment for differences in baseline characteristics, PPI use was independently asso

201 None of the sickle cell disease baseline characteristics predicted accurately a complica

202 Baseline characteristics, procedural and in-hospital out

203 were performed to adjust for differences in baseline characteristics, procedural indications, and co

204 Our objective was to compare the baseline characteristics, resources, and treatments with

205 Graft and patient baseline characteristics, risk factors for failure, surg

206 None of the patients' baseline characteristics (shock, use of angiotensin-conv

207 tigators to share individual patient data on baseline characteristics, stroke severity and type, end-

208 2 factorial design minimizing differences in baseline characteristics such as age, sex, and duration

209 Nut consumption was associated with some baseline characteristics such as lower body mass index a

210 greater impact on NO2 and PM2.5 change than baseline characteristics, suggesting urban design and la

211 d December 2005, 9792 patients with complete baseline characteristics, surgery procedure, and follow-

212 The ProgStar cohorts have baseline characteristics that encompass a wide range of

213 In patients with baseline characteristics that included female sex, body

214 Baseline characteristics that were examined included dem

215 Despite differences in baseline characteristics, the 4 strongest predictors of

216 After accounting for baseline characteristics, the risk of death remained hig

217 The study groups were similar with regard to baseline characteristics; the median age of the patients

218 confounders such as MS relapses, as well as baseline characteristics, through the use of inverse pro

219 s were observed between them with respect to baseline characteristics, thus emphasizing the comparabi

220 Baseline characteristics, time to failure or last visit,

221 This followed examination of baseline characteristics to define the degree of physica

222 r agents from 2000 to 2008 were analyzed for baseline characteristics, toxicities, responses, and sur

223 To compare baseline characteristics, visual acuity (VA) and morphol

224 propensity matching, the only difference in baseline characteristics was the use of neoadjuvant chem

225 Correlations between outcomes and baseline characteristics were assessed via meta-regressi

226 Baseline characteristics were balanced between groups, a

227 Baseline characteristics were balanced between groups: m

228 Baseline characteristics were balanced between the 2 gro

229 All 16 baseline characteristics were balanced in the matched co

230 lled (Ona + Bev, n = 64; Pla + Bev, n = 65), baseline characteristics were balanced.

231 Baseline characteristics were collected and, if publishe

232 Baseline characteristics were collected to identify the

233 Baseline characteristics were comparable across treatmen

234 Baseline characteristics were comparable between the tre

235 Baseline characteristics were comparable by arm.

236 Baseline characteristics were comparable for all groups

237 Baseline characteristics were comparable in the treatmen

238 th either access route (total 708 patients), baseline characteristics were comparable.

239 Baseline characteristics were comparable.

240 Baseline characteristics were compared between the 2 gro

241 sed the risk of transformation or death when baseline characteristics were considered with a hazard r

242 Baseline characteristics were described as proportions a

243 spital volume was divided into 3 groups, and baseline characteristics were described.

244 Baseline characteristics were determined from administra

245 Baseline characteristics were examined, and changes in c

246 servational studies that did not control for baseline characteristics were excluded, catheter-related

247 Baseline characteristics were generally similar between

248 Baseline characteristics were more adverse in patients w

249 Baseline characteristics were not different according to

250 Baseline characteristics were not different between gend

251 phics, clinical characteristics, and imaging baseline characteristics were presented by descriptive s

252 Baseline characteristics were recorded, and each patient

253 No differences in baseline characteristics were seen in patients not trans

254 Baseline characteristics were similar across cohorts.

255 Baseline characteristics were similar across groups and

256 Baseline characteristics were similar among groups.

257 Baseline characteristics were similar among groups.

258 Baseline characteristics were similar among patients wit

259 The baseline characteristics were similar among the 11,140 p

260 Baseline characteristics were similar between all partic

261 Baseline characteristics were similar between arms.

262 Baseline characteristics were similar between both the g

263 Baseline characteristics were similar between groups.

264 Baseline characteristics were similar between groups.

265 Baseline characteristics were similar between groups.

266 Baseline characteristics were similar between groups.

267 In the ILLUMENATE Pivotal Study, baseline characteristics were similar between groups: 50

268 Baseline characteristics were similar between groups: pa

269 Baseline characteristics were similar between the 2 grou

270 Baseline characteristics were similar between the 2 rand

271 Baseline characteristics were similar between the groups

272 Baseline characteristics were similar between the groups

273 Baseline characteristics were similar between the groups

274 Baseline characteristics were similar between the halope

275 Baseline characteristics were similar between the study

276 ts with known IHD (18% women, 82% men), most baseline characteristics were similar between women and

277 Baseline characteristics were similar for both groups.

278 Baseline characteristics were similar for PA versus TR.

279 Demographic and baseline characteristics were similar in all arms.

280 Baseline characteristics were similar in both groups.

281 Baseline characteristics were similar in both groups.

282 Baseline characteristics were similar in both zoledronic

283 Baseline characteristics were similar in the 2 groups.

284 Baseline characteristics were similar in the two groups;

285 Baseline characteristics were similar, except more men (

286 Baseline characteristics were similar.

287 Baseline characteristics were similar.

288 Between-group baseline characteristics were similar.

289 Baseline characteristics were similar; however, there we

290 Baseline characteristics were well balanced among sub-co

291 Results Baseline characteristics were well balanced among the ar

292 Patient demographic and baseline characteristics were well balanced between the

293 Despite variation in indications for GPIs, baseline characteristics were well balanced between the

294 Baseline characteristics were well balanced between trea

295 e DES- and BMS-treated groups whose observed baseline characteristics were well-balanced.

296 mpared with matched patients with comparable baseline characteristics who underwent atrial fibrillati

297 o identify 68 triads of patients matched for baseline characteristics who were treated with early ant

298 nalysis was used to determine association of baseline characteristics with multidrug resistance.

299 we extracted the most recent measurement of baseline characteristics (within 2 years of diagnosis) f

300 Propensity score matching for 19 baseline characteristics yielded 664 patient pairs.